Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled
12 4월 2024 - 8:30PM
Evome Medical Technologies Inc (the “
Company” or
“
Evome”) highlighted the strengthening credit
relationship with Pathward, N.A. (“
Pathward”), the
Company’s senior lender. As the Company works to sell non-core
business units to reduce acquisition debt in an effort to improve
operational profitability, Pathward provides working capital to
fuel revenue growth of the Company’s new Biodex products. Pathward
has featured the strong and growing relationship with Evome as an
example of its willingness to fund growth companies:
Evome Medical Technologies enjoys multi-year
expansion with financing from Pathward Web
link:https://www.pathward.com/news/evome-medical-technologies-enjoys-multi-year-expansion-with-fina/
This focus on revenue growth and market
expansion has led the Company’s operating subsidiary, Biodex
Rehab Systems, LLC (“Biodex”), to launch a new,
high-tech product called the RST (Reactive Step Trainer),
previously announced by the Company. The RST was launched by the
Company at the American Physical Therapy Association Combined
Sections Meeting in Boston on February 15, 2024. The RST is
designed to improve balance and reduce tripping and falling,
particularly among elderly patients. The Reactive Step Trainer can
provide repetitive conditioning training along with random and
on-demand perturbation challenges, designed to help patients
improve their compensatory step strategies and reduce fall risk. It
has been meticulously engineered to be cost-effective, ensuring
accessibility to a wider range of patients, while also prioritizing
functionality to effectively cater to the clinical requirements of
Physical Therapists.
Looking ahead, Evome plans to continue its
innovation with the upcoming launch of the SpaceTek Knee™. This
isokinetic device, co-developed with NASA, represents another
milestone in Evome's commitment to advancing medical technology and
improving patient outcomes while improving margins and increasing
sales by democratizing its technology to a broader market.
“As we focus on the higher margin Biodex product
line, we will work towards shedding non-core assets for the purpose
of reducing existing acquisition debt,” said CEO Mike Seckler.
“Simbex was an excellent example of this strategy. By selling
Simbex, we both paid down a significant portion of acquisition debt
and we are able to focus our time, capital and energy on the Biodex
product line.”
The Company also announced that the non-binding
letter of intent (LOI) to extend acquisition debt related to the
Company’s acquisition of Simbex LLC in 2021, previously announced
by the Company on February 8, 2024, has been cancelled and the
unsecured and subordinated debt will revert to its previous status
as an unsecured subordinated debt of the Company.
Mike Seckler Chief Executive Officer Tel: 1
(800) 760-6826 Email: Info@Salonaglobal.com
Cautionary Statements
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Certain statements contained in this press
release constitute "forward-looking information" within the
meaning of the Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws. These statements can be
identified by the use of forward-looking terminology such as
“expects” “believes”, “estimates”, "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
and "anticipate", and similar expressions as they relate to the
Company, including: the Company reducing debt by divesting
non-core business units and the financial implications of such
divestitures; the benefits of using the RST; and the Company
launching its SpaceTek Knee™ product toward the end of the year.
All statements other than statements of historical fact may be
forward-looking information. Such statements reflect the Company's
current views and intentions with respect to future events, and
current information available to the Company, and are subject to
certain risks, uncertainties and assumptions, including: the
Company successfully identifying a buyer for a non-core business
and negotiating and closing a sale; the Company having the
necessary capital to complete its business objectives. The Company
cautions that the forward-looking statements contained herein are
qualified by important factors that could cause actual results to
differ materially from those reflected by such statements. Such
factors include but are not limited to the general business and
economic conditions in the regions in which the Company
operates; the ability of the Company to execute on key
priorities, including the successful completion of acquisitions,
business retention, and strategic plans and to attract,
develop and retain key executives; difficulty integrating newly
acquired businesses; ongoing or new disruptions in the supply
chain, the extent and scope of such supply chain disruptions, and
the timing or extent of the resolution or improvement of such
disruptions; the ability to implement business strategies and
pursue business opportunities; disruptions in or attacks
(including cyber-attacks) on the Company’s information
technology, internet, network access or other voice or data
communications systems or services; the evolution of various types
of fraud or other criminal behavior to which the Company is
exposed; the failure of third parties to comply with their
obligations to the Company or its affiliates; the impact of
new and changes to, or application of, current laws and
regulations; granting of permits and licenses in a highly
regulated business; the overall difficult litigation
environment, including in the United States; increased competition;
changes in foreign currency rates; increased funding costs
and market volatility due to market illiquidity and competition
for funding; the availability of funds and resources to pursue
operations; critical accounting estimates and changes to
accounting standards, policies, and methods used by the
Company; the occurrence of natural and unnatural catastrophic
events and claims resulting from such events; as well as
those risk factors discussed or referred to in the Company’s
disclosure documents filed with United States Securities and
Exchange Commission and available at www.sec.gov, and with the
securities regulatory authorities in certain provinces of Canada
and available at www.sedarplus.ca. Should any factor affect
the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results
or events predicted. Any such forward-looking information is
expressly qualified in its entirety by this cautionary
statement. Moreover, the Company does not assume responsibility
for the accuracy or completeness of such forward-looking
information. The forward-looking information included in this
press release is made as of the date of this press release and
the Company undertakes no obligation to publicly update or revise
any forward-looking information, other than as required by
applicable law.
Evome Medical Technologies (TSXV:EVMT)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Evome Medical Technologies (TSXV:EVMT)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024